Actos® Injury Claims

Thank you for visiting our website.  If you are seeking representation for an injury you may have received from taking Actos® , please take a moment and fill out our consultation form.  Compensation may be available. 
 
There is no charge or obligation for us to review your claim. Click here to begin.

Actos® use Linked to Bladder Cancer

On June 15, 2011, the U.S. Food and Drug Administration (FDA) issued a drug safety communication warning patients and health professionals that use of pioglitazone (Actos—Takeda) for more than 1 year may be associated with an increased risk of bladder cancer. Patients who were on pioglitazone therapy for more than 12 months had a 40% increased risk of bladder cancer compared with patients who had never used the drug.

The active ingredient in Actos® is also contained in other drugs, namely Actoplus Met®, Actoplus Met XR®, and Duetact®

What is Actos®?
Oral diabetes medication Actos® (generic name pioglitazone) is made by Takeda Pharmaceutical Company and co-marketed in the United States by Eli Lilly Pharmaceuticals. Actos® and related drugs are used to control type-2 diabetes in patients whose condition is not adequately controlled by diet and exercise alone.

Actos® belongs to a class of drugs called Thiazolidinedione drugs, which help to treat Type-2 diabetes by lowering blood glucose levels and increasing the body’s sensitivity to insulin. This drug may be prescribed alone (as Actos®) or in combination with other active ingredients such as metformin (sold as Actoplus met) or glimepiride (sold as duetact). A patient’s drug regiment may also include insulin or other medications in addition to those containing pioglitazone.

Type-2 diabetes, which affects approximately 18 to 20 million Americans, is characterized by high blood glucose levels caused by the body’s inability to properly use insulin. This disease, left untreated, can lead to blindness, kidney problems, and cardiovascular disease.

If you or a family member took Actos®, Actoplus Met®, Actoplus Met XR®, or Duetact® and you believe developed bladder cancer, call us toll free at 877-767-3108 or click the link below to begin the claim process. Consultations are free and our response to your claim is prompt.

Click here for a free case review

First Name:	*
Last Name:	*
Email Address:
Contact Number:	*
Comments:	*